Search

Displaying results 611 - 620 of 3917 in total
  1. Drug

    Piflufolastat F 18

    go.drugbank.com/drugs/DB14805
    ApprovedInvestigational

    [L34324] On July 28, 2023, the EMA also approved Piflufolastat F18 under the brand name PYLCLARI for primary staging or localizing recurrence of prostate cancer.[L47586] … Prostate cancer is the most common non-cutaneous malignancy affecting men in North America[A235344] - despite this, an ongoing challenge in prostate cancer therapy is the difficulty in imaging the extent

  2. Drug

    Sevoflurane

    go.drugbank.com/drugs/DB01236
    ApprovedInvestigationalVet approved

    [L42340] It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient.

  3. Drug

    Bromfenac

    go.drugbank.com/drugs/DB00963
    ApprovedWithdrawn

    Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239]

    Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-Narcotic
  4. Drug

    Gepotidacin

    go.drugbank.com/drugs/DB12134
    ApprovedInvestigational

    [L52680] In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicated urinary tract infections in select patients.

  5. Drug

    Noscapine

    go.drugbank.com/drugs/DB06174
    Approved

  6. Drug

    Gadopiclenol

    go.drugbank.com/drugs/DB17084
    ApprovedInvestigational

    The product label includes a black box warning regarding the increased risk for NSF among patients with impaired elimination of the drugs.[L43817] … Gadopiclenol is a gadolinium-based contrast agent (GBCA) based on a pyclen macrocyclic structure.

  7. Drug

    Galiximab

    go.drugbank.com/drugs/DB04901
    Investigational

    Galiximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.

  8. Drug

    Dexibuprofen

    go.drugbank.com/drugs/DB09213
    ApprovedWithdrawn

    Dexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties.

    Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Non COX-2 selective NSAIDS
  9. Drug

    Capivasertib

    go.drugbank.com/drugs/DB12218
    ApprovedInvestigational

    [A262021,A262026,A262031] On November 17th, 2023, capivasertib, under the brand name TRUQAP, was approved by the FDA for the treatment of adult patients HR-positive, HER2-negative locally advanced or … This approval is based on favorable results obtained from the CAPItello-291 trial, where the combination of capivasertib and [fulvestrant] reduced the risk of disease progression or death by 50% versus

  10. Drug

    Somapacitan

    go.drugbank.com/drugs/DB15093
    ApprovedInvestigational

    [A219146] Somapacitan was granted FDA approval on 28 August 2020.[L15666]